Moderna Inc. ($MRNA) Stock Forecast: Up 5.3% Today

What is Moderna Inc.?

Moderna, Inc. (NASDAQ: MRNA) is a leading biotechnology company renowned for its pioneering mRNA technology, notably in vaccine and therapeutic development. The stock witnessed a significant surge in value today following recent company updates and announcements.

Why is Moderna Inc. going up?

MRNA stock is up 5.3% on Feb 2, 2026 18:40

• Moderna's upward momentum can be associated with the encouraging insights shared during the 44th Annual J.P. Morgan Healthcare Conference. The company emphasized its strategic business expansion, progress in product development, and anticipated financial performance over the upcoming years.
• The market responded positively to Moderna's detailed three-year business plan revealed during its Analyst Day. The plan included forecasts for revenue growth, expansion of its vaccine portfolio, and a heightened focus on oncology and rare disease treatments.
• Investors seemingly responded to Moderna's growth potential, despite concerns raised regarding declining revenue and projected performance compared to industry standards. The optimistic narrative presented by Moderna during recent conferences likely overshadowed these underlying challenges in the near term.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 43%

Moderna, Inc. (NASDAQ:MRNA) shares have surged 43% in the last month, bringing its 12-month gain to 21%. Despite a relatively low price-to-sales (P/S) ratio of 7.7x compared to the biotech industry average, the company's declining revenue (down 56% last year) and projected underperformance against industry revenue growth (11% vs. 134% per annum) indicate a potential lack of future growth. This outlook contributes to its lower P/S ratio, suggesting that the stock's recent strong performance might not be sustained given the fundamental challenges.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/moderna-incs-nasdaqmrna-price-is-right-but-growth-is-lacking-1

NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2

NanoViricides (NYSE American: NNVC) highlights the critical need for broad-spectrum antiviral drugs, referencing the current severe influenza wave dominated by the H3N2 K variant. The company emphasizes that its drug candidate, NV-387, is effective against influenza, RSV, and coronaviruses. NV-387 is designed to overcome established antiviral drug resistance by targeting a host-side feature (heparan sulfate) that viruses cannot easily mutate away from.

https://www.pnj.com/press-release/story/21391/nanoviricides-comments-on-the-need-for-broad-spectrum-antivirals-in-light-of-the-current-influenza-wave-nv-387-is-effective-against-h3n2/

Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

Moderna, Inc. announced business updates and pipeline progress at the 44th Annual J.P. Morgan Healthcare Conference, focusing on growing sales, launching new infectious disease products, and delivering pivotal readouts in oncology, rare disease, and infectious disease. The company expects significant financial performance in 2025 and 2026, including increased revenue, reduced operating expenses, and a growing cash balance, driven by its seasonal vaccine franchise and late-stage clinical trials. Moderna also highlighted key milestones for its seasonal vaccines and oncology and rare disease therapeutics planned for 2026.

https://www.vcstar.com/press-release/story/19495/moderna-provides-business-and-pipeline-updates-at-44th-annual-j-p-morgan-healthcare-conference/

Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates

Moderna unveiled its three-year business strategy at its Analyst Day, projecting up to 10% revenue growth in 2026 and targeting cash breakeven by 2028. The company plans to expand its seasonal vaccine franchise to up to six approved products by 2028, driven by new launches and geographic expansion, while increasing investment in oncology and rare disease therapeutics. Moderna also announced projected improvements in GAAP operating expenses and secured a $1.5 billion term loan facility to bolster its financial position.

https://www.tcpalm.com/press-release/story/12478/moderna-analyst-day-highlights-pipeline-progress-and-business-strategy-updates/

Lexicon Pharmaceuticals Announces Key Stock Offering amid Strategic Funding Efforts

Lexicon Pharmaceuticals (LXRX) has announced a public stock offering to fund research and development, despite its stock trading down by -18.75% amidst concerns over clinical trial results and regulatory hurdles. The company faces significant financial challenges, evidenced by negative profitability ratios, but possesses a strong gross margin and current ratio. This strategic move, managed by Jefferies and Piper Sandler, aims to provide financial stability and capitalize on future market opportunities, though it may lead to further shareholder dilution and continued bearish pressure in the short term.

https://stockstotrade.com/news/lexiconpharmaceuticalsinc-lxrx-news-2026_01_31/

Trending Today

Hasbro Inc. ($HAS) Stock Forecast: Up 5.0% Today

Cardano ($ADA) Crypto Forecast: Up 5.6% Today

MicroVision Inc. ($MVIS) Stock Forecast: Down 5.8% Today

Western Digital Corporation ($WDC) Stock Forecast: Up 7.9% Today

GameStop Corp. ($GME) Stock Forecast: Up 5.1% Today

Intel Corporation ($INTC) Stock Forecast: Up 5.4% Today

Monolithic Power Systems Inc. ($MPWR) Stock Forecast: Up 5.1% Today

Natural Gas ($GAS) Commodity Forecast: Down 13.4% Today

Astrazeneca PLC ($AZN) Stock Forecast: Down 0.4% Today

Moderna Inc. ($MRNA) Stock Forecast: Up 5.3% Today

Moderna Inc. Price History

30.00.2026 - MRNA Stock was down 5.4%

• A recent partnership for the development of mRNA-3927 for propionic acidemia highlights Moderna's dedication to broadening its portfolio beyond vaccines.
• The appointment of Dr. David Berman as Chief Development Officer brings valuable expertise in immunotherapy, potentially indicating a shift towards advancing clinical-stage therapies.
• Despite recent positive developments, concerns over financial pressures and an ambitious profitability target set for 2028 have led to a bearish market reaction.
• Investors may be cautious about the leadership transition from Dr. Jacqueline Miller to Dr. David Berman, as such changes can introduce uncertainties impacting stock performance.

30.00.2026 - MRNA Stock was down 5.7%

• Moderna's stock experienced a bearish movement following the announcement of the departure of its chief medical officer amidst other executive departures within the company.
• The appointment of Dr. David Berman as the new Chief Development Officer was not enough to offset the negative sentiment, as investors may be concerned about the leadership changes and potential impact on the company's future direction.
• The partnership with Recordati to develop an mRNA therapy for a rare metabolic disorder was a positive development, but it seems the market focused more on the internal leadership changes at Moderna.
• The overall market reaction suggests that investors are closely monitoring Moderna's executive team transitions and the company's ability to maintain its innovative edge in mRNA technology amidst leadership shake-ups.

27.00.2026 - MRNA Stock was up 6.0%

• MRNA stock experienced a bullish movement today.
• The positive market sentiment towards MRNA could be attributed to recent advancements in personalized cancer vaccines by another company, potentially boosting confidence in the biotech sector.
• Additionally, positive developments in the biotech industry, such as progress with a therapy for bladder cancer by another company, may have created a ripple effect of optimism among investors, benefiting companies like MRNA.
• Overall, the growing interest and potential breakthroughs in the biotech field seem to have contributed to the bullish movement in MRNA stock today.

27.00.2026 - MRNA Stock was down 5.2%

• Moderna (MRNA) underwent a period of bearish movement, potentially influenced by positive developments and growth projections of major competitors in the oncology market, including Merck (MRK), Oncolytics Biotech Inc. (ONCY), and other industry participants.
• Merck's (MRK) anticipated rise in earnings and revenues, progress in its oncology pipeline, and revised growth forecasts might have redirected investor attention from Moderna, leading to a decline in its stock performance.
• Analysts' call for enhanced clarity on long-term growth prospects at Merck, despite its notable performance, may have prompted investor apprehensions regarding Moderna's competitiveness and future growth trajectory in biotechnology.
• References to AI stocks presenting superior upside potential compared to Merck could have shifted investor focus towards alternative investment options, thereby contributing to the downward trend in Moderna's stock value.

23.00.2026 - MRNA Stock was down 10.9%

• The stock's decline may have been driven by profit-taking by investors following a recent 4% rally linked to positive five-year follow-up data for their mRNA cancer vaccine in collaboration with Merck.
• Concerns about potential competition or market positioning for Moderna in the oncology sector could have arisen with the amendment of the license agreement between Terns Pharmaceuticals and Hansoh for TERN-701 rights.
• Investor focus and capital might have been redirected towards the banking sector, particularly awaiting Itaú Unibanco's Q4 results, contributing to Moderna's downward trend.
• Despite the promising long-term prospects in oncology, external factors and short-term market dynamics possibly influenced the bearish performance today.

23.00.2026 - MRNA Stock was down 9.4%

• Moderna's stock saw a strong bearish movement possibly due to the announcement of limiting investment in new late-stage vaccine trials, reflecting concerns over achieving returns amidst regulatory hurdles and opposition in the US market.
• The groundbreaking five-year follow-up data for their mRNA cancer vaccine, which demonstrated positive results in high-risk melanoma patients, might have been overshadowed by the decision to curb vaccine trial investments, leading to investor uncertainty.
• The amended license agreement with Hansoh for TERN-701 by Terns Pharmaceuticals could have also impacted Moderna's stock negatively, as it potentially shifts focus and resources away from certain therapeutic products.
• Overall, the market may be reacting to the shifting priorities and strategies within Moderna, as it navigates challenges in the regulatory landscape and transitions towards personalized cancer treatments, impacting investor sentiment and stock performance.

23.00.2026 - MRNA Stock was down 10.7%

• The stock's decline could be attributed to profit-taking or concerns about vaccine distribution challenges.
• Positive updates on Lucid Group, Materion Corp, and Terns Pharmaceuticals might have shifted investor focus away from Moderna.
• Other companies' positive news and Itaú Unibanco's upcoming investor meeting could have added to the downward pressure on Moderna's stock.
• Despite today's bearish movement, Moderna's long-term outlook remains optimistic due to its crucial role in the pandemic response and continuous vaccine innovations.

02.01.2026 - MRNA Stock was up 5.3%

• Moderna's upward momentum can be associated with the encouraging insights shared during the 44th Annual J.P. Morgan Healthcare Conference. The company emphasized its strategic business expansion, progress in product development, and anticipated financial performance over the upcoming years.
• The market responded positively to Moderna's detailed three-year business plan revealed during its Analyst Day. The plan included forecasts for revenue growth, expansion of its vaccine portfolio, and a heightened focus on oncology and rare disease treatments.
• Investors seemingly responded to Moderna's growth potential, despite concerns raised regarding declining revenue and projected performance compared to industry standards. The optimistic narrative presented by Moderna during recent conferences likely overshadowed these underlying challenges in the near term.

28.00.2026 - MRNA Stock was down 8.4%

• An analyst initiated coverage on Moderna with an "equal weight" rating and a $25.00 price target, indicating a significant downside potential from its current price. This negative sentiment from analysts likely contributed to the bearish movement.
• The weak fundamentals of Moderna, such as negative EPS and revenue declines, could have further fueled investor concerns and led to the sell-off.
• The lack of growth in revenue and poor financial outlook for biotech companies like BioNTech SE, may have cast a shadow on Moderna's prospects, impacting its stock performance.
• Overall, the combination of negative analyst ratings, weak financial fundamentals, and broader industry concerns about revenue growth in the biotech sector likely contributed to Moderna's bearish market movement today.

22.00.2026 - MRNA Stock was up 8.2%

• Moderna's stock surged by 4% following the groundbreaking five-year follow-up data for their mRNA cancer vaccine, showing a significant reduction in the risk of relapse or death in high-risk melanoma patients. This success not only boosted investor confidence in Moderna's technology but also solidified its position as a major player in oncology.
• The announcement of Moderna curbing investments in vaccine trials due to US backlash had a positive impact on the stock, with shares jumping by 10.16% in morning trading. This strategic shift towards personalized cancer treatments in response to regulatory hurdles demonstrates the company's adaptability and focus on long-term growth.
• The partnership between Bristol Myers Squibb and Janux Therapeutics in developing novel T cell engagers for solid tumors may have indirectly contributed to Moderna's bullish movement by highlighting the potential in oncology treatments, further fueling optimism in the biotech sector.
• Overall, Moderna's bullish market movement today can be attributed to its groundbreaking cancer vaccine data, strategic shift towards personalized treatments, and positive investor sentiment towards advancements in oncology therapies.

29.00.2026 - MRNA Stock was up 5.0%

• Moderna's bullish movement could be attributed to positive sentiment surrounding its ongoing developments and potential in the healthcare sector.
• The reduction in stake by Federated Hermes Inc. and director Noubar Afeyan might have initially raised concerns, but the market likely focused more on the broader positive outlook for the company.
• The strong performance of healthcare stocks in the past month, including Moderna, reflects investor confidence in the sector, further boosting MRNA's upward momentum.
• With the focus on NLRP3 inhibitors by other companies like Eli Lilly and BioAge Labs, the overall excitement and advancements in healthcare innovation could have positively influenced Moderna's stock performance.

29.00.2026 - MRNA Stock was up 5.7%

• Moderna's stock soared as investors exhibited confidence in the company's innovative mRNA technology and its promising prospects for growth.
• The decision by Federated Hermes Inc. and director Noubar Afeyan to reduce their stake may have sparked some initial market uncertainty, but the prevailing sentiment leaned towards positivity.
• The stock's remarkable performance could also be linked to its inclusion in the top healthcare stocks list, showcasing its resilience and growth potential in the sector.
• The increased market interest in healthcare stocks, evident from the leading ETFs and the focus on NLRP3 inhibitors by other entities, likely contributed to the further elevation of Moderna's stock price.